IBONYSEPharmaceutical PreparationsFiscal year ends December 31
IMPACT BIOMEDICAL INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$3.06+0.38 (+14.18%)
Close on Oct 19, 2026
- Market cap
- $329.93M
- P/E (TTM)
- –
- Dividend yield
- –
Impact Biomedical statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Impact Biomedical | Industry median |
|---|---|---|
| Market Cap | $329.93M | $164.85M |
| Enterprise Value | $333.17M | $87.06M |
| PS Ratio | 9426.66 | 3.60 |
| PB Ratio | 30.65 | 2.03 |
Enterprise value
| Measure | Impact Biomedical | Industry median |
|---|---|---|
| EV / Sales | 9519.11 | 2.43 |
Income (trailing twelve months)
| Measure | Impact Biomedical | Industry median |
|---|---|---|
| Revenue | $35.00K | $57.94M |
| Operating Income | -$5.11M | -$21.44M |
| Pretax Income | -$1.80M | -$14.45M |
| Net Income | $789.00K | -$22.46M |
| EBITDA | -$3.97M | -$16.91M |
Margins
| Measure | Impact Biomedical | Industry median |
|---|---|---|
| Operating Margin | -14597.1% | -44.5% |
| Pretax Margin | -5154.3% | -13.0% |
| Profit Margin | 2254.3% | -39.2% |
| EBITDA Margin | -11331.4% | -31.3% |
Returns
| Measure | Impact Biomedical | Industry median |
|---|---|---|
| Return on Equity (ROE) | 371.3% | -53.1% |
| Return on Assets (ROA) | 4.41% | -41.0% |
| Return on Capital Employed (ROCE) | -34.8% | -37.8% |
Growth
| Measure | Impact Biomedical | Industry median |
|---|---|---|
| Revenue Growth (3Y CAGR) | -13.8% | 2.25% |
Balance sheet
| Measure | Impact Biomedical | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $10.00K | $62.42M |
| Net Cash (Debt) | $10.00K | $15.68M |
| Net Cash Per Share | $0.00 | $0.66 |
| Equity (Book Value) | $10.77M | $48.79M |
| Book Value Per Share | $0.10 | $1.36 |
| Tangible Book Value | -$5.66M | $23.06M |
| Working Capital | -$1.73M | $75.77M |
Financial position
| Measure | Impact Biomedical | Industry median |
|---|---|---|
| Current Ratio | 0.16 | 3.30 |
| Quick Ratio | 0.00 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Impact Biomedical | Industry median |
|---|---|---|
| Operating Cash Flow | -$508.00K | -$12.35M |
Efficiency
| Measure | Impact Biomedical | Industry median |
|---|---|---|
| Asset Turnover | 0.00 | 0.38 |
| Revenue Per Employee | $17.50K | $398.96K |
| Profits Per Employee | $394.50K | -$703.34K |
| Employee Count | 2 | 74 |
Dividends and yields
| Measure | Impact Biomedical | Industry median |
|---|---|---|
| Earnings Yield | 0.24% | -22.7% |
Shares
| Measure | Impact Biomedical | Industry median |
|---|---|---|
| Shares Outstanding | 107,821,000 | 58,179,650 |
| Shares Change (QoQ) | 0.00% | 0.54% |
| Float | 106,378,000 | 49,173,100 |
| Shares Held by Insiders | 1.34% | 11.6% |
Scores
| Measure | Impact Biomedical | Industry median |
|---|---|---|
| Altman Z-Score | 66.92 | -0.24 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from Impact Biomedical's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.